<DOC>
	<DOCNO>NCT02631993</DOCNO>
	<brief_summary>Cure leukemia hematopoietic stem cell transplantation ( HSCT ) sustain anti-leukemic effect graft cell ( graft-versus-leukemia ( GVL ) ) . However , know whether tumor-immunity affect photochemotherapy ( psoralene photosensitization ultraviolet light radiation ) administer attenuate graft-versus host disease ( GVHD ) . The present study aim investigate happen GVL photochemotherapy aGVHD predominantly retrospective set 10-years follow-up HSCT</brief_summary>
	<brief_title>Photochemotherapy Graft-versus-leukemia Acute-leukemia</brief_title>
	<detailed_description>This 10-year follow-up patient Acute-myeloid-leukemia ( AML ) acute-lymphatic-leukemia ( ALL ) . AML diagnose French-American-British criterion ( FAB-criteria ) ALL separate chief form immunohistological method . All patient underwent myeloablative Hematopoietic Stem Cell Transplantation ( HSCT ) 1985 2005 center allogeneic stem cell transplantation ( CAST ) Karolinska University Hospital . All patient receive GVHD-prophylaxis . The risk relapse HSCT grade low-risk disease first complete remission HSCT , disease state classify high-risk . Eligible patient receive photochemotherapy ( Ultraviolet radiation type A skin photosensitize oral 8-methoxypsoralen ) acute graft-versus-host disease ( GVHD within 100-days HSCT ) . Photochemotherapy may give primary later aGVHD therapy . Patients aGVHD booster dos stem-cells donor-lymphocyte-infusions include . Additional treatment register present . Methotrexate consider additional GVHD treatment intravenous methotrexate part govern GVHD prophylaxis effect methotrexate secondary aGVHD treatment weak . At start , end , maximum two week end PUVA-therapy GVHD diagnose accordance Glucksberg indexed CIBMTR . Relapse diagnose leukemic cell present extra medullary bone marrow biopsy ≥ 30 % blast . Early relapse diagnose medulla contain 5 - 30 % blast The primary outcome GVL i.e . abscence relapse malignant disease minimal residual disease ( MRD ) i.e . threaten relapse malignant disease demand donor lymphocyte infusion ( DLI ) . Primary predictor : Time-to-treatment photochemotherapy day 0 - 7 vs. start day 8 ≤ aGVHD . Continuous secondary predictor : Time-to-treatment photochemotherapy continuous variable ( day start aGVHD ) . Binary secondary predictor : Risk ( Low/High ) , Sibling donor-recipient ( Yes/No ) , Mismatched relate ( Yes/No ) , Unrelated donor ( Yes/No ) , ( Male recipient female graft ( Yes/No ) , T-cell depletion Anti-Thymocyte Globulin ( Yes/No ) . Categorical secondary predictor : AGVHD organ disease stage disease grade ; Skin ( + , ++ , +++ , ++++ ) , Liver ( + , ++ , +++ , ++++ ) , Gastro-intestinal ( + , ++ , +++ , ++++ ) , Center International Blood Marrow Transplant Research CIBMTR index ( A , B , C , D ) respectively . Statistical analysis : Cox proportional Hazards ratio use conduct univariate data analysis adequate variable patient characteristic disease towards primary outcome . In analysis , death , DLI retransplantation due graft-failure treat compete event . The primary predictor ( binary ) binary categorical covariates identify patient disease characteristic include multivariate forward regression analysis , control backward regression base log-likelihood method . P=0.05 consider significant p=0.10 trend . StatSoft , Inc. ( 2013 ) . STATISTICA ( data analysis software system ) , version 12. www.statsoft.com . use statistical computation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Furocoumarins</mesh_term>
	<mesh_term>Ficusin</mesh_term>
	<criteria>Eligible patient receive photochemotherapy ( Ultraviolet radiation type A skin photosensitize oral 8methoxypsoralen ) acute graftversushost disease ( GVHD within 100days HSCT ) . Photochemotherapy may give primary later aGVHD therapy . Patients aGVHD booster dos stemcells donorlymphocyteinfusions include .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Psoralen</keyword>
	<keyword>UVA</keyword>
	<keyword>Time-to-treatment</keyword>
	<keyword>GVL</keyword>
</DOC>